Ann Plast Surg. 2008 Oct;61(4):419-24.

Topical imiquimod therapy for lentigo maligna.

Source

Division of Plastic Surgery, University of Toronto, ON, Canada.

Abstract

Lentigo maligna (LM) presents a challenge for complete surgical excision. Imiquimod is a topical immune-response modifier that acts on the immune system. We report our experience using imiquimod 5% cream as a surgical alternative for treatment of LM. Consecutive patients between December 2004 and February 2006 with LM were treated with topical imiquimod. Data on patient and lesion characteristics, side effects of therapy, posttreatment biopsy results, and follow-up was collected. Seven patients were treated with imiquimod 5 nights/wk for 12.4 weeks. Complete histologic and clinical resolution was seen in 86% (6 of 7 patients), at 19.1 months follow-up. Side effects included erythema (86%) and crusting (71%), resulting in dose alteration in 71% of patients. Topical imiquimod therapy demonstrates a high response rate for treatment of LM, with tolerable side effects. Further investigation into its efficacy in the treatment of LM in controlled clinical trials is warranted.

PMID:: 18812714; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Case Reports

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Skin Cancer - MedlinePlus Health Information

Supplemental Content

Related citations

Treatment of lentigo maligna with imiquimod before staged excision. [Dermatol Surg. 2008]
Treatment of lentigo maligna with imiquimod before staged excision.
Cotter MA, McKenna JK, Bowen GM. Dermatol Surg. 2008 Feb; 34(2):147-51. Epub 2007 Dec 17.
[Lentigo maligna treated with 5% imiquimod cream]. [Actas Dermosifiliogr. 2005]
[Lentigo maligna treated with 5% imiquimod cream].
Martín T, Ojeda A, Martínez S, Vera A. Actas Dermosifiliogr. 2005 Dec; 96(10):700-2.
Topical imiquimod immunotherapy in the management of lentigo maligna. [Clin Exp Dermatol. 2004]
Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM, Russell-Jones R, Barlow RJ. Clin Exp Dermatol. 2004 Jan; 29(1):15-21.
Review Imiquimod in the treatment of lentigo maligna. [Br J Dermatol. 2006]
Review Imiquimod in the treatment of lentigo maligna.
Rajpar SF, Marsden JR. Br J Dermatol. 2006 Oct; 155(4):653-6.
Review [Imiquimod in the treatment of lentigo maligna]. [Actas Dermosifiliogr. 2011]
Review [Imiquimod in the treatment of lentigo maligna].
Nagore E, Botella-Estrada R. Actas Dermosifiliogr. 2011 Oct; 102(8):559-62. Epub 2011 May 4.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Topical imiquimod therapy for lentigo maligna.
Topical imiquimod therapy for lentigo maligna.
Ann Plast Surg. 2008 Oct ;61(4):419-24.

PubMed
The burden of obesity among a national probability sample of veterans.
The burden of obesity among a national probability sample of veterans.
J Gen Intern Med. 2006 Sep ;21(9):915-9.

PubMed
Genetic characterization of the NS gene indicates co-circulation of two sub-line...
Genetic characterization of the NS gene indicates co-circulation of two sub-lineages of highly pathogenic avian influenza virus of H5N1 subtype in Northern Europe in 2006.
Virus Genes. 2008 Feb ;36(1):117-25. Epub 2008 Jan 3 .

PubMed
Recommendations from the EGAPP Working Group: can tumor gene expression profilin...
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Genet Med. 2009 Jan ;11(1):66-73.

PubMed
Improved survival in a multidisciplinary short bowel syndrome program.
Improved survival in a multidisciplinary short bowel syndrome program.
J Pediatr Surg. 2008 Jan ;43(1):20-4.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: